Exchange: NASDAQ·Updated 07:53 PM EDT
News
all
press releases
Is Tempus AI Worth Buying as Growth Improves but Valuation Stays High?
TEM's faster growth, rising data demand and reimbursement potential strengthen the bull case, but high valuation and cash burn keep risks in focus.
Zacks
More News
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on July 21, 2026, the Compensation Committee of Guardants Board of Directors approved the granting of restricted stock units (RSUs) representing 46,044 shares of its common stock to 149 new non-executive...
Business Wire
Amazon To Rally Around 55%? Here Are 10 Top Analyst Forecasts For Friday
Analysts change outlook & price targets for Crocs, Monolithic Power, Axos Financial, Amazon, Karyopharm, Apple, Guardant Health, Pagaya Tech.read more...
Benzinga
Guardant Health (GH) Reports Q2 Loss, Tops Revenue Estimates
Guardant Health (GH) delivered earnings and revenue surprises of -5.00% and +6.01%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Guardant Health (GH) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for Guardant Health (GH) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks
Guardant Health Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended June 30, 2026. Second Quarter 2026 Financial Highlights For the three-month period ended June 30, 2026, as compared to the same period of 2025: Reported total revenue of...
Business Wire
Guardant Health to Participate in Upcoming Investor Conferences
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences. Canaccord Genuity 46th Annual Growth Conference in Boston, MA Fireside chat on Wednesday, August 12th at 3:00 p.m. Eastern Time Morgan...
Business Wire
Actor and Cancer Advocate Patrick Dempsey Stars in Emotional Tribute Video From Guardant Health Memorializing Those Who Have Lost Their Lives to Colorectal Cancer
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the launch of a new video featuring actor and cancer advocate Patrick Dempsey that highlights the more than 55,000 Americans who will lose their lives to colorectal cancer (CRC) this year1, a majority of which...
Business Wire
TG Therapeutics (TGTX) to Report Q2 Results: Wall Street Expects Earnings Growth
TG Therapeutics (TGTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Guardant Health (GH) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Guardant Health (GH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks

Advertisement|Remove ads.